Mercury Laboratories Ltd
Incorporated in 1962, Mercury Laboratories Ltd manufactures and exports Pharmaceutical
items of gyno and pediatrics.[1]
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
| Free Cash Flow |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit |
Ratios
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Direct export share of total revenue % ・Standalone data |
|
||||||||
| Export to Africa share of total exports % ・Standalone data |
|||||||||
| Export to Americas share of total exports % ・Standalone data |
|||||||||
| Export to Asia share of total exports % ・Standalone data |
|||||||||
| Number of permanent employees employees ・Standalone data |
|||||||||
| Manufacturing capacity (tablets) tablets per month ・Standalone data |
|||||||||
| Number of countries with direct export presence countries ・Standalone data |
|||||||||
Extracted by Screener AI
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Certificate under Reg 74(5) of SEBI (DP) regulations, 2018 for the quarter ended on September 30, 2026 is attached
-
Announcement under Regulation 30 (LODR)-Change in Directorate
- Mr. Dilip Ramanlal Shah ceased as Non-Executive Director after 45th AGM on September 28, 2026.
-
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
- Mercury Laboratories disclosed 45th AGM e-voting results; dividend approved, several director/remuneration resolutions failed.
-
Shareholder Meeting / Postal Ballot-Outcome of AGM
- Mercury Laboratories held its 45th AGM on September 28, 2026; approved ₹3.50 dividend and other resolutions.
- Closure of Trading Window
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Business Overview:[1][2][3]
MLL is engaged in formulating, developing, manufacturing, exporting, marketing and distributing pharmaceutical
drugs and therapeutic compliance medicines. The products of the company are in the segment of gynae and pediatric. Its major brands are K-Win, K-Stat, T-Stat, Merizyme and Promolact